Z

Zeiss

Corporate venture capital for deep-tech startups

Biotech/Pharma Key Account Manager

Full-TimeUpdated on 10/23/2026
$67k - $84k/yr+ Performance bonus + Sales commissions
Mid
Bachelor's, Master's
California, USA
RemoteRemote in California; travel up to 60%.
Sales & Account ManagementField Sales
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A bachelor's degree or higher in biological science or bioengineering is preferred.
  • Working knowledge of high-end microscopy, including laser scanning microscopy, and imaging techniques beyond simple image capture and manipulation, such as automated time lapse with Z-stack.
  • Prior technical sales experience and experience managing a field coverage area for technical sales or product support are preferred.
  • Prior experience working in a research position within a pharmaceutical or biotech company environment is preferred.
  • Knowledge and experience in biological applications and workflow solutions, including spatial biology, high-content imaging, image analysis, and bioinformatics, are preferred.
  • Strong verbal and written communication skills are required to align internal stakeholders and engage customers effectively.
  • Ability to collaborate effectively across cross-functional teams.
  • Willingness to continuously acquire product and application knowledge independently.
  • Knowledge and understanding of laboratory safety requirements for BSL 1, 2, and 3 environments, and specimen handling of Level 3 and lower pathogenic biohazards, including bacteria, viruses, fungi, parasites, and prions.
  • Good knowledge of Microsoft Office.
  • Willingness to travel up to 60% of the time.
  • A driving record in good standing, a valid driver's license, and ability to drive a company-provided car or van.
  • Must have valid employment authorization to work in the United States.
  • Must be able to procure a passport for international travel.
  • Ability to lift microscope equipment up to 75 pounds.
Responsibilities
  • Develop and execute strategic account plans to achieve sales targets and drive revenue growth in biotech and pharmaceutical markets.
  • Own and drive the full sales cycle using consultative, value-based selling methodologies, including the ZEISS Selling Process and Challenger, from lead qualification and needs discovery through demonstrations, proposal development, and deal closure.
  • Assume commercial responsibility for the Core Light Microscopy portfolio, deliver in-person and remote presentations and demonstrations, and partner with PASS on complex 3D system opportunities.
  • Identify new business opportunities and expand relationships within existing accounts.
  • Serve as the primary customer point of contact and ensure timely communication and resolution of inquiries or issues.
  • Maintain accurate pipeline visibility and forecasting through disciplined use of the customer relationship management system, ensuring opportunities are properly qualified and up to date.
  • Prioritize daily activities and manage time to advance sales and support initiatives efficiently.
  • Build long-term customer relationships through frequent face-to-face engagement and collaboration with scientists, departmental leaders, and procurement teams.
  • Manage the customer relationship as ZEISS's primary point of contact, set clear expectations, and proactively manage challenges when plans do not proceed as expected.
  • Coordinate with Product Application Sales Specialists, service engineers, sales support, logistics, and business partners on delivery timelines, installations, training, onboarding, and ongoing customer success.
  • Continuously develop knowledge across the ZEISS microscopy portfolio, including product capabilities, applications, and software functionality.
  • Build understanding of biotech and pharma technical imaging and analysis needs, and business trends such as funding and budgeting cycles.
  • Communicate biotech and pharma market trends, customer insights, and industry dynamics to local and global management and marketing teams.
  • Generate opportunities across the Life Science portfolio within the assigned biotech/pharma territory.
  • Conduct targeted outreach and awareness initiatives, such as email campaigns and ZEISS On Your Campus workshops, to build pipeline, generate interest, and expand market presence.
  • Network within the biotech and pharmaceutical community locally, nationally, and as appropriate, globally.
  • Optimize demonstration resources across onsite, remote, and ZMCC formats to maximize return on investment.
  • Work with e-commerce, materials research, and business partner teams to ensure portfolio coverage aligns with company strategy.
  • Build effective working relationships with field service, back-office sales support, and logistics teams to streamline order processing, system delivery, installation, and ongoing support.
  • Manage travel, expenses, and reporting independently and prudently.
  • Care for demonstration equipment and ensure its timely return.
  • Follow laboratory safety practices and remain aware of potential risks during customer site visits.
  • Conduct activities in accordance with ZEISS policies, standards, and professional expectations.
  • Serve as a ZEISS brand ambassador and engage in continuous professional development, including CurioZ training and self-directed learning.
  • Achieve annual sales order intake targets of $2 million in Year 1, $3 million in Year 2, and $4 million in Year 3, with a balanced system mix and active funnel growth across the ZEISS solutions portfolio.
  • Maintain strong price realization against global list price through value-based selling and minimal discounting.
  • Ensure timely, complete, and accurate customer relationship management updates to support reliable pipeline visibility and forecasting.
  • Expand and retain strategic biotech and pharmaceutical accounts through sustained relationship development beyond single transactions.
  • Work on assigned teams on defined projects as directed by management, as needed.
Desired Qualifications
  • Bachelor's degree or higher in biological science or bioengineering from an accredited college or university.
  • Prior technical sales experience and experience managing a field coverage area for technical sales or product support.
  • Prior experience working in a research position within a pharmaceutical or biotech company environment.
  • Knowledge and experience in biological applications and workflow solutions, including spatial biology, high-content imaging, image analysis, and bioinformatics.

About the company

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-half 2025/26 revenue reached €5.841 billion, with EBIT rising to €955 million.
  • ZEISS CLINIC 360 won FDA 510(k) clearance on August 19, 2026.
  • EURETINA 2026 launches expanded retina imaging, cataract systems, and DORC brand integration.

What critics are saying

  • ZEISS Meditec plans up to 1,000 cuts by 2029, signaling margin pressure.
  • Göttingen workers entered mediation in February 2026 after Zeiss targeted roughly 140 jobs.
  • ASML scanner timing controls ZEISS SMT revenue; any slip delays optics demand immediately.

What makes Zeiss unique

  • ZEISS supplies ASML's exclusive EUV optics, anchoring High-NA lithography through 2030.
  • ZEISS Medical Technology bundles imaging, software, and surgery across one ophthalmic workflow stack.
  • ZEISS CLINIC 360 and Collaborative Care tie devices, cloud analytics, and referrals together.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Performance Bonus

Company News

Associated Press
Oct 12th, 2026
ZEISS launches NLX X-ray inspection and DUNE wafer warpage correction for advanced chip packaging

ZEISS Semiconductor Manufacturing Technology (SMT) has launched two systems for advanced chip packaging: ZEISS NLX and ZEISS DUNE. The company announced them in San Francisco on October 12, 2026, as chips grow more complex. ZEISS NLX inspects the inside of chip packages without damaging them. It helps manufacturers spot defects in connections between stacked dies early, and it handles 300-millimetre wafers in both process development and high-volume production. ZEISS DUNE measures the topography of a wafer and corrects wafer bow individually. This helps avoid yield losses in downstream processing and prepares bonding processes. ZEISS SMT is showing the systems at SEMICON West, alongside its photomask tools. The company is also marking 100 years of business in the US in 2026.

PR Newswire
Sep 24th, 2026
ZEISS unveils retinal imaging and surgical innovations at EURETINA 2026

ZEISS Medical Technology has announced expansions to its ZEISS Retina Workflow at the EURETINA 2026 congress in Vienna. The company introduced the ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device for streamlined retinal diagnostics. ZEISS also unveiled the HMDmd CR3, a head-mounted 3D display that connects with the ZEISS ARTEVO 850 surgical microscope. The company reported that its DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL vitreoretinal surgical dyes reached a 3 million milestone. Additionally, ZEISS announced that the DORC brand will be consolidated under the ZEISS brand name, unifying the company's ophthalmic offerings. The DORC TDC VELOCE cutter continues to show improvements in 27G vitrectomy procedures, with clinical data suggesting up to 41% shorter core vitrectomy times.

PR Newswire
Sep 17th, 2026
ZEISS expands retinal imaging portfolio with new ALTA DUO 300 multimodal OCT device

ZEISS Medical Technology has expanded its retinal imaging portfolio with the launch of ZEISS ALTA DUO 300, a fully automated, compact multimodal imaging solution. The device combines optical coherence tomography (OCT) and fundus photography in a single unit, designed to provide efficient retinal assessment for eye care practices. The ALTA DUO 300 features four key diagnostic technologies: automated structural OCT with reference database and reporting, true colour fundus camera, AI-enhanced OCT-Angiography, and full chamber depth anterior OCT scanning. The device aims to integrate retinal imaging into everyday patient care through simplified workflows. The product will be showcased at the European Society of Retina Specialists congress in Vienna from 1-4 October and will be available in select markets later in 2026.

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.